We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Membrane Protein Structure Visualized Using Emerging X-Ray Technology despite Existing Damage

By LabMedica International staff writers
Posted on 23 Jan 2011
Australian researchers have found a way to measure the structure of membrane proteins in spite of being damaged when using X-ray free-electron lasers (XFELs), a discovery that will help fast track the development of targeted drugs using new XFELs technology. More...


Approximately 70% of drugs on the market today depend on the activity of membrane proteins, which are complex molecules that form the membranes of the cells in our body. A major problem for the design of new pharmaceuticals, often known as the "membrane protein problem,” is that they do not form the crystals needed to enable further investigation of the structure to design better drugs.

A large international effort is being undertaken to determine the structures of membrane proteins using XFELs--large facilities that create such a bright beam of X-rays it is possible to see the X-ray light bouncing off a single molecule without forming a crystal.

Prof. Keith Nugent, and ARC Federation fellow and director of the Australian Research Council Center of Excellence for Coherent X-ray Science (CXS) at the University of Melbourne (Australia) reported that a key problem was that the light from an XFEL was so bright a molecule would start to disintegrate in less than one thousandth of a millionth of a millionth of a second.

In an article published online December 19, 2010, in the journal Nature Physics, Prof. Nugent and Associate Prof. Harry Quiney from the ARC Center of Excellence for Coherent X-ray Science (CXS) have developed a method by which the damage from the XFEL pulse may be included in the data analysis. Associate Prof. Quiney, also from the School of Physics at the University of Melbourne, reported that the study's findings revealed that high-resolution molecular structures may be obtained from X-ray scattering data using a few-femtosecond pulse from an XFEL, even if the interaction resulted in significant electronic damage to the target. "This result has far-reaching implications for the future development of structural biology, because it removes a significant obstacle to the practical realization of the molecular microscope using XFEL sources,” he said.

The technology also provides significant clues into the complex, raging, and little-understood interactions that are driven by the interaction of an XFEL pulse with an atom, molecule, or solid. The scientists' approach uses advanced molecular physics and precise data analysis to determine a new approach to measuring molecular structure. Although still at the theoretic and computation level when put into practice, this finding should remove a major hurdle in the path to solving the membrane protein problem.

In 2010, CXS signed an agreement with Japanese colleagues and will host the 4th Asia-Oceania Workshop on Science with X-ray Free Electron Lasers in 2011.

Prof. Nugent noted that this was an extremely exciting time for X-ray science. "My colleagues and I are convinced that our recent work is a critically important step forward,” he said. "We are very much looking forward to working with our Japanese colleagues in the coming years.”

The first XFEL began operating at Stanford University in Palo Alto, CA, USA, in 2009 and the second, the SPring8 facility in Harima Science Park City, Hyogo Prefecture, Japan, will start in 2011. A third is under construction in Europe to commence in 2014.

Related Links:
University of Melbourne



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.